Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects
Primary Purpose
Obesity, Overweight
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Milk
Soy
Sponsored by
About this trial
This is an interventional basic science trial for Obesity focused on measuring Inflammation, Oxidative stress
Eligibility Criteria
Inclusion Criteria:
- Body mass index (BMI) 25-29.9 (n=10); 30-34.9 kg/m2 (n=10)
- Age 18-50 years
- Weight stable: no more than 3 kg weight loss during past three months
Exclusion Criteria:
- BMI < 25 or >35
- Type II diabetes requiring the use of any oral antidiabetic agent and/or insulin (because of confounding effects on ROS)
- Adverse response to study foods (lactose intolerance, dairy intolerance, dairy allergy); this will be determined by self-report.
- history or presence of significant metabolic disease which could impact on the results of the study (i.e. endocrine, hepatic, renal disease)
- history of eating disorder
- presence of active gastrointestinal disorders such as malabsorption syndromes
- pregnancy or lactation
- use of obesity pharmacotherapeutic agents within the last 6 months
- use of over-the-counter anti-obesity agents (e.g. those containing phenylpropanalamine, ephedrine and/or caffeine) within the last 6 months
- Recent (current or past 12 weeks) use of any psychotropic medication
- Recent (past four weeks) initiation of an exercise program
- Recent (past twelve weeks) initiation of hormone replacement therapy or change in HRT regimen
- Recent (past twelve weeks) initiation of hormonal birth control or change in hormonal birth control regimen
- Recent (current or past 12 weeks) history of smoking
Sites / Locations
- The University of Tennessee
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Soy
Milk
Arm Description
Soy-based supplement to normal diet
Milk-based supplement to normal diet
Outcomes
Primary Outcome Measures
Plasma malondialdehyde
Plasma 8-isoprostane F2-alpha
Plasma tumor necrosis factor alpha
plasma interleukin 6
Plasma C-reactive protein
Plasma MCP-1
Plasma interleukin 15
Plasma adiponectin
Secondary Outcome Measures
Plasma lipids
Plasma insulin
vitamin D
Body composition
Full Information
NCT ID
NCT00948038
First Posted
July 28, 2009
Last Updated
July 28, 2009
Sponsor
University of Tennessee
Collaborators
Dairy Management Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00948038
Brief Title
Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
May 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Tennessee
Collaborators
Dairy Management Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to determine the acute effects of a dairy supplement compared to a soy supplement on oxidative and inflammatory stress in overweight and obese subjects in the absence of any changes in adiposity.
Detailed Description
Obesity is associated with sub-clinical chronic oxidative and inflammatory stress, both of which are major contributors to obesity-associated co-morbidities. Calcitriol (1, 25-(OH)2-D3) regulates adipocyte lipid metabolism, while dietary calcium inhibits obesity by suppression of calcitriol. We have recently shown calcitriol to increase oxidative stress and to stimulate the expression and release of inflammatory cytokines, while inhibiting the expression and release of anti-inflammatory cytokines. We have also shown that inhibition of calcitriol with high calcium diets decreases both adipose tissue and systemic oxidative and inflammatory stress in a mouse model of obesity. Moreover, dairy exerted a greater effect on both oxidative and inflammatory stress. These mice also exhibited significant reductions in adiposity, which could lead to confounding, as this reduction will independently reduce oxidative and inflammatory stress. However, the supporting cellular/mechanistic data indicate an effect which is independent of adiposity reduction. Consequently, we propose that low calcium diets exacerbate oxidative and inflammatory stress and that high dairy diets can attenuate both independently of changes in adiposity, thereby significantly reducing the risk of obesity-associated co-morbidities. Accordingly, the objective of this study is to determine the acute effects of a dairy-rich diet on oxidative and inflammatory stress in overweight and obese subjects in the absence of any changes in adiposity.
Twenty subjects (10 obese and 10 overweight) will undergo a randomized crossover study of low dairy and high dairy eucaloric diets. Each dietary period will be four weeks, and the two dietary periods will be separated by a four-week washout period. Primary outcomes will be circulating indices of oxidative stress and of inflammation. Secondary outcomes include blood pressure, circulating glucose, insulin, lipids, calcium-regulatory hormones and body composition.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight
Keywords
Inflammation, Oxidative stress
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Soy
Arm Type
Active Comparator
Arm Description
Soy-based supplement to normal diet
Arm Title
Milk
Arm Type
Experimental
Arm Description
Milk-based supplement to normal diet
Intervention Type
Dietary Supplement
Intervention Name(s)
Milk
Intervention Description
Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Soy
Intervention Description
Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
Primary Outcome Measure Information:
Title
Plasma malondialdehyde
Time Frame
28 days
Title
Plasma 8-isoprostane F2-alpha
Time Frame
28 days
Title
Plasma tumor necrosis factor alpha
Time Frame
28 days
Title
plasma interleukin 6
Time Frame
28 days
Title
Plasma C-reactive protein
Time Frame
28 days
Title
Plasma MCP-1
Time Frame
28-days
Title
Plasma interleukin 15
Time Frame
28 days
Title
Plasma adiponectin
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Plasma lipids
Time Frame
28 days
Title
Plasma insulin
Time Frame
28 days
Title
vitamin D
Time Frame
28 days
Title
Body composition
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Body mass index (BMI) 25-29.9 (n=10); 30-34.9 kg/m2 (n=10)
Age 18-50 years
Weight stable: no more than 3 kg weight loss during past three months
Exclusion Criteria:
BMI < 25 or >35
Type II diabetes requiring the use of any oral antidiabetic agent and/or insulin (because of confounding effects on ROS)
Adverse response to study foods (lactose intolerance, dairy intolerance, dairy allergy); this will be determined by self-report.
history or presence of significant metabolic disease which could impact on the results of the study (i.e. endocrine, hepatic, renal disease)
history of eating disorder
presence of active gastrointestinal disorders such as malabsorption syndromes
pregnancy or lactation
use of obesity pharmacotherapeutic agents within the last 6 months
use of over-the-counter anti-obesity agents (e.g. those containing phenylpropanalamine, ephedrine and/or caffeine) within the last 6 months
Recent (current or past 12 weeks) use of any psychotropic medication
Recent (past four weeks) initiation of an exercise program
Recent (past twelve weeks) initiation of hormone replacement therapy or change in HRT regimen
Recent (past twelve weeks) initiation of hormonal birth control or change in hormonal birth control regimen
Recent (current or past 12 weeks) history of smoking
Facility Information:
Facility Name
The University of Tennessee
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37996
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Dairy Modulation of Oxidative and Inflammatory Stress in Overweight and Obese Subjects
We'll reach out to this number within 24 hrs